Townsend Richard Nolan 4

What Happened
Richard Nolan, CEO of Lexeo Therapeutics (LXEO), reported an open‑market sale of 10,173 shares on February 18, 2026. The shares were disposed at a weighted average price of $6.38 per share, generating proceeds of approximately $64,924. The filing indicates this sale was to cover tax obligations arising from the release of restricted stock units (RSUs), so it is a routine tax‑withholding sale rather than a signal of a change in outlook.

Key Details

• Transaction date: 2026-02-18; Form 4 filed 2026-02-20 (filed within the typical 2‑business‑day deadline).
• Shares sold: 10,173; weighted average price: $6.38; total proceeds ≈ $64,924.
• Price range: executed in multiple trades at $6.22–$6.50; weighted average reported ($6.38). Reporting person will provide trade-by-trade breakdown upon SEC/issuer/holder request.
• Reason/footnote: Sale made to cover tax obligations on RSU release (F1).
• Holdings note: F3 states the reporting person’s holdings include 261,349 Restricted Stock Units; the Form 4 does not list a total post‑transaction common‑share count in the provided summary.

Context
Sales to cover tax withholding on RSU vesting are common and usually considered routine (coded as “S” for sale and noted here as tax withholding). This is not an options exercise or gift; it’s a straightforward disposition of vested shares to satisfy taxes. Retail investors should view this as administrative rather than a directional insider buy/sell signal.